Secreted immunodominant Mycobacterium tuberculosis antigens are processed by the cytosolic pathway.
Exposure to Mycobacterium tuberculosis can result in lifelong but asymptomatic infection in most individuals. Although CD8(+) T cells are elicited at high frequencies over the course of infection in both humans and mice, how phagosomal M. tuberculosis Ags are processed and presented by MHC class I molecules is poorly understood. Broadly, both cytosolic and noncytosolic pathways have been described. We have previously characterized the presentation of three HLA-I epitopes from M. tuberculosis and shown that these Ags are processed in the cytosol, whereas others have demonstrated noncytosolic presentation of the 19-kDa lipoprotein as well as apoptotic bodies from M. tuberculosis-infected cells. In this paper, we now characterize the processing pathway in an additional six M. tuberculosis epitopes from four proteins in human dendritic cells. Addition of the endoplasmic reticulum-Golgi trafficking inhibitor, brefeldin A, resulted in complete abrogation of Ag processing consistent with cytosolic presentation. However, although addition of the proteasome inhibitor epoxomicin blocked the presentation of two epitopes, presentation of four epitopes was enhanced. To further examine the requirement for proteasomal processing of an epoxomicin-enhanced epitope, an in vitro proteasome digestion assay was established. We find that the proteasome does indeed generate the epitope and that epitope generation is enhanced in the presence of epoxomicin. To further confirm that both the epoxomicin-inhibited and epoxomicin-enhanced epitopes are processed cytosolically, we demonstrate that TAP transport and new protein synthesis are required for presentation. Taken together, these data demonstrate that immunodominant M. tuberculosis CD8(+) Ags are processed and presented using a cytosolic pathway.
Grotzke
Jeff E
JE
Division of Infectious Diseases, Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239, USA.
Siler
Anne C
AC
Lewinsohn
Deborah A
DA
Lewinsohn
David M
DM
D000818:Animals; D017951:Antigen Presentation / Q000276:immunology*; D000942:Antigens, Bacterial / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003600:Cytosol / Q000276:immunology* / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D004721:Endoplasmic Reticulum / Q000276:immunology / Q000378:metabolism; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D006056:Golgi Apparatus / Q000276:immunology / Q000378:metabolism; D006801:Humans; D016056:Immunodominant Epitopes / Q000276:immunology* / Q000378:metabolism; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000276:immunology; D046988:Proteasome Endopeptidase Complex / Q000276:immunology / Q000378:metabolism
D000942:Antigens, Bacterial; D018984:Epitopes, T-Lymphocyte; D016056:Immunodominant Epitopes; C072681:Mycobacterium tuberculosis antigens; D046988:Proteasome Endopeptidase Complex
J Biol Chem. 1999 Feb 5;274(6):3363-71
9920878
Annu Rev Cell Dev Biol. 2004;20:367-94
15473845
Immunity. 2004 Aug;21(2):155-65
15308097
J Immunol. 1998 Jun 1;160(11):5448-54
9605147
J Immunol. 2006 Sep 15;177(6):3525-33
16951311
Science. 1998 Oct 2;282(5386):121-5
9756476
J Exp Med. 2001 Jul 2;194(1):1-12
11435468
Microbes Infect. 2005 Apr;7(4):776-88
15823514
Nature. 1999 Mar 4;398(6722):77-80
10078533
Cell. 2007 Jun 29;129(7):1287-98
17604718
PLoS Pathog. 2009 Apr;5(4):e1000374
19360129
Curr Top Microbiol Immunol. 2002;269:87-99
12224518
Traffic. 2000 Mar;1(3):235-47
11208107
PLoS Pathog. 2007 Sep 21;3(9):1240-9
17892322
J Immunol. 2007 Sep 15;179(6):3973-81
17785835
Science. 2004 Jun 18;304(5678):1800-4
15155913
Blood. 2003 Dec 15;102(13):4448-55
12933572
J Immunol. 2001 Aug 1;167(3):1274-82
11466343
J Bacteriol. 2007 Aug;189(16):6028-34
17557817
Immunity. 1996 Apr;4(4):349-55
8612129
Nat Immunol. 2008 Aug;9(8):937-44
18587399
Eur J Cell Biol. 2001 Jan;80(1):31-40
11211933
Nat Med. 2003 Aug;9(8):1039-46
12872166
Nat Immunol. 2003 Apr;4(4):375-9
12598896
Infect Immun. 2000 Dec;68(12):6997-7002
11083824
Immunity. 2006 Oct;25(4):607-17
17027300
J Immunol. 2006 Jul 1;177(1):437-42
16785540
Nature. 1993 Jan 28;361(6410):359-62
7678924
J Exp Med. 1994 Oct 1;180(4):1499-509
7931080
J Exp Med. 1998 May 18;187(10):1633-40
9584141
J Exp Med. 2009 Feb 16;206(2):399-410
19153244
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4033-8
15753315
Infect Immun. 2008 Sep;76(9):4199-205
18591224
Annu Rev Immunol. 2001;19:93-129
11244032
J Immunol. 2001 Nov 15;167(10):5549-57
11698425
J Immunol. 2003 Sep 1;171(5):2242-50
12928368
Cell. 1994 May 20;77(4):525-35
8187174
J Immunol. 2001 Jan 1;166(1):447-57
11123323
J Immunol. 2006 Jul 15;177(2):983-90
16818754
J Biol Chem. 2006 Dec 29;281(52):39925-34
17088258
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12420-5
14557547
J Immunol. 2000 Feb 15;164(4):2016-20
10657653
Infect Immun. 2005 Feb;73(2):703-11
15664908
J Virol. 2007 Nov;81(21):11925-36
17699574
Clin Exp Immunol. 2003 Oct;134(1):70-7
12974757
J Immunol. 2005 Dec 1;175(11):7474-83
16301655
Nat Immunol. 2004 Jul;5(7):670-7
15224092
Am J Respir Crit Care Med. 2003 Dec 1;168(11):1346-52
12969871
J Immunol. 2000 Jun 15;164(12):6147-57
10843664
J Exp Med. 2002 Dec 2;196(11):1473-81
12461082
Science. 1995 Jan 13;267(5195):243-6
7809629
J Immunol. 2001 Jan 1;166(1):439-46
11123322